ArticleMolecular and clinical oncology2016

A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients.

Kuniaki Aridome et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.